


CDx Announcement

FoundationOne®CDx  
is now FDA-approved as a  
**companion diagnostic**  
**for PEMAZYRE™** (pemigatinib)






**Cholangiocarcinoma** is a rare cancer, diagnosed in approximately **8,000 patients annually**.<sup>1</sup> Because it is difficult to detect, it's often diagnosed later when the prognosis is poor and treatment options are limited.<sup>2</sup>

*FGFR2* fusions or rearrangements occur in

**10-16%**

of intrahepatic  
cholangiocarcinoma  
(iCCA) patients.<sup>3,4,5</sup>





Foundation Medicine testing can help identify *FGFR2* fusions or select rearrangements in cholangiocarcinoma patients who may be eligible for treatment with **PEMAZYRE™** (pemigatinib).



**FOUNDATIONONE® CDx**

FoundationOne®CDx is a next-generation sequencing based *in vitro* test intended for use by healthcare professionals for advanced cancer patients with solid tumors. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is FDA-approved as a companion diagnostic to identify patients who may benefit from treatment with a specific list of therapies (listed in Table 1 in the full intended use) in accordance with the approved therapeutic product labeling. Additional genomic findings, other than those listed in Table 1, may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment or clinical trial option, or that all relevant alterations will be detected. Some patients may require a biopsy. For the complete label, including important risk information, please visit [www.foundationmedicine.com/f1cdx](http://www.foundationmedicine.com/f1cdx)

# Order FoundationOne® CDx

Web: [home.foundationmedicine.com](http://home.foundationmedicine.com)

Email: [client.services@foundationmedicine.com](mailto:client.services@foundationmedicine.com)

Call: **888.988.3639**

PEMAZYRE™ is a trademark of Incyte Corporation.

## References

<sup>1</sup> American Cancer Society, cancer.org, accessed 4/27/20

<sup>2</sup> Uhlig J, et al. Ann Surg Oncol. 2019;26:1993-2000.

<sup>3</sup> Graham RP, et al. Hum Pathol. 2014;45:1630-1638.

<sup>4</sup> Farshidfar F, et al. Cell Rep. 2017;18(11):2780-2794.

<sup>5</sup> Ross JS et al. The Oncologist. 2014;19:235-242.

